Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· June 16, 2026

The Zacks Analyst Blog Highlights Albemarle, Dycom Industries and Murphy USA

View original at finance.yahoo.com
The Zacks Analyst Blog Highlights Albemarle, Dycom Industries and Murphy USA For Immediate Release Chicago, IL – June 16, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Trump suggested a peace deal with Iran could be struck in Europe over the weekend ahead of the G7 summit.

    60% confidence
  • The Fed is not expected to take any action at the June 16-17 FOMC meeting; all market focus will be on Wednesday's policy statement and press conference.

    60% confidence
  • U.S. consumer inflation increased at its fastest pace in three years in May 2026 after the Iran war drove a surge in energy prices.

    60% confidence
  • President Trump reiterated his desire for lower interest rates.

    60% confidence
  • Wars in the Middle East and Ukraine are set to dominate the G7 summit in France.

    60% confidence
  • Markets are increasingly pricing in the chance that stubbornly high inflation will mean U.S. interest rates go up again in coming months, rather than down.

    60% confidence
  • Japan's central bank policy rate is expected to rise to 1.0%, which would be the first time in over three decades.

    60% confidence
  • French officials described the G7 summit as a success if Trump just stays for the whole event, having left the 2025 version early.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com